Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial

Rheumatoid Arthritis

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Lancet Rheumatol

Cope AP, Jasenecova M, Vasconcelos JC, Qureshi S, van Schie KA, Filer A, Raza K, D'Agostino MA, McInnes IB, Siebert S, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Mankia K, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga TWJ, Toes REM, Georgiou E, Kelly J, Murphy C, Prevost AT, ALTO Study Investigators

doi: 10.1016/S2665-9913(25)00371-6

Immune Response

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Lancet

Tindale LC, Richardson JS, Anderson DM, Mendy J, Muhammad S, Loreth T, Tredo SR, Ramanathan R, Jenkins VA, Bedell L, Ajiboye P, EBSI-CV-317-005 Study Group

doi: 10.1016/S0140-6736(25)00372-1

Rheumatoid Arthritis

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Ann Rheum Dis

Taylor PC, Mease PJ, de Vlam K, Mpofu S, Wetzel D, Stevens AM, Wiens B, Koskinen LO, Ohlman S, Feldwisch J, Frejd FY, Brun NC, Brandt-Juergens J, Drescher E, Dokoupilova E, Rowińska-Osuch A, Abdel-Kader Martin N, Behrens F

doi: 10.1016/j.ard.2025.02.019

Rheumatoid Arthritis

Effect of an intensive smoking cessation intervention on smoking cessation and disease activity in patients with rheumatoid arthritis: a randomised controlled trial

Rheumatology (Oxford)

Esbensen BA, Thomsen T, Roelsgaard IK, Østergaard M, Hetland ML, Andersen L, Tønnesen H, Semb AG, Christensen R

doi: 10.1093/rheumatology/keaf448

Further Publications Dermatology

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study

Lancet

Kavanagh D, Bomback AS, Vivarelli M, Nester CM, Remuzzi G, Zhao MH, Wong EKS, Wang Y, Krishnan I, Schuhmann I, Trapani AJ, Webb NJA, Meier M, Israni RK, Smith RJH, APPEAR-C3G investigators

doi: 10.1016/S0140-6736(25)01148-1

Fibromyalgia

Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial

Ann Rheum Dis

Rasmussen MU, Christensen R, Wæhrens EE, Henriksen M, Duhn PH, Bliddal H, Amris K

doi: 10.1016/j.ard.2025.07.008

Rheumatoid Arthritis

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Ann Rheum Dis

Wientjes MHM, Atiqi S, Wolbink GJ, Nurmohamed MT, Boers M, Hooijberg F, Rispens T, de Vries A, van Vollenhoven RF, Ramiro S, van Herwaarden N, van den Bemt BJF, den Broeder AA

doi: 10.1016/j.ard.2025.03.015

Rheumatoid Arthritis

Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial

Lancet Rheumatol

De Marco G, Hensor EMA, Helliwell PS, Sultan S, Dubash SR, Michelena X, Coates LC, Emery P, Tan AL, McGonagle D, Marzo-Ortega H

doi: 10.1016/S2665-9913(25)00156-0

Immunodeficiency

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

Lancet

Colson AE, Mills AM, Ramgopal MN, Bettacchi C, Osiyemi OO, Hinestrosa F, Crofoot G, Katner HP, Gatanaga H, Johnson M, Diamond TL, Barninger E, Eves K, Su FH, Xu Y, Klopfer SO, Stamm LM, Fox MC, Lahoulou R

doi: 10.1016/S0140-6736(25)01948-8

Related content

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Effect of an intensive smoking cessation intervention on smoking cessation and disease activity in patients with rheumatoid arthritis: a randomised controlled trial

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study

Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial